Pharmaceutical

Climb Bio enters licensing deal with Mabworks for CLYM116 development

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Jan 12, 2025 - 06:00
Climb Bio enters licensing deal with Mabworks for CLYM116 development
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.
Read the original article

Tags:

Previous Article

Alzheimer’s total prevalent cases to reach 22.51 million in 8MM in 2033

Next Article

A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

For volunteers at an eating disorder hotline, being replaced by an AI chatbot carried a painful cost

For volunteers at an eating disorder hotline, being rep...

Jun 28, 2023

Addressing industry challenges through flexible, personalized eCOA solutions

Addressing industry challenges through flexible, person...

Aug 9, 2024

STAT+: Hot antitrust environment hangs over called-off merger between Cigna and Humana

STAT+: Hot antitrust environment hangs over called-off ...

Dec 11, 2023